Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to determine whether therapy that has been shown to be beneficial for mitochondrial diseases is also beneficial for Chronic Fatigue Syndrome (CFS) patients. This study is a chart review of previous CFS patients who received daily conditioning exercise, a high protein diet and nutraceutical therapy (ENT). Prescribed nutraceutical supplements included alpha-lipoic acid, acetyl-L-carnitine, omega-3fatty acids (maxDHA), coenzyme Q10 (CoQ10), plus a multivitamin.

Twelve CFS male and female patients between the ages of 20-70 years will be recruited to participate in this pilot study. Subjects will be eligible to participate if they meet the criteria for CFS of the Centers for Disease Control and Prevention (CDC). These include persistent, unexplained fatigue for at least 6 months, concurrent with four of the following: impaired memory/concentration, sore throat, new headaches, unrefreshing sleep, muscle pain, multi-joint pain, tender lymph nodes, and post-exertional malaise.

Clinical Trial Description

The etiology and pathogenesis of chronic fatigue syndrome (CFS) is poorly understood. Although therapies have been proposed, none has been particularly effective. A preceding viral infection is believed to cause mitochondrial dysfunction in genetically susceptible individuals, resulting in overwhelming fatigue, myalgia and brain fuzziness. The purpose of this study was to determine whether therapy that has been shown to be beneficial for mitochondrial diseases is also beneficial for CFS.

Patients received daily conditioning exercise, a high protein diet and nutraceutical therapy (ENT). Prescribed nutraceutical supplements incldued alpha-lipoic acid, acetyl-L-carnitine, omega-3fatty acids (maxDHA), coenzyme Q10 (CoQ10), plus a multivitamin, which were selected to enhance mitochondrial function and antioxidant action. Following the institution of ENT, patients had received this therapy for varying lengths of time, ranging from 12 to 40 months. ;

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01872351
Study type	Observational
Source	Columbia University
Contact
Status	Withdrawn
Phase	Phase 1
Start date	November 2011
Completion date	November 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05454683` - Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	N/A
Completed	`NCT01686074` - Motor Control in Chronic Fatigue Syndrome and Fibromyalgia	N/A
Completed	`NCT02075489` - Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans	N/A
Completed	`NCT01651754` - Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome	N/A
Completed	`NCT00540254` - Behavioral Insomnia Therapy With Chronic Fatigue Syndrome	Phase 1/Phase 2
Active, not recruiting	`NCT00071162` - Genetics of Fibromyalgia	N/A
Withdrawn	`NCT04870476` - Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome	N/A
Completed	`NCT05730660` - Quercetin Phytosome® Chronic Fatigue Syndrome	N/A
Recruiting	`NCT04542161` - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Phase 2
Recruiting	`NCT03807973` - Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.	Phase 1
Recruiting	`NCT05719493` - Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)	N/A
Recruiting	`NCT05967052` - Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation	Phase 2
Terminated	`NCT01730495` - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome	Phase 2
Completed	`NCT01156909` - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome	Phase 2
Completed	`NCT01650636` - Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process	N/A
Completed	`NCT01046370` - A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia	N/A
Completed	`NCT00100412` - Hyporeactivity and Gulf War Illness	N/A
Recruiting	`NCT06128967` - A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial	Phase 3
Completed	`NCT02669212` - Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health	N/A
Not yet recruiting	`NCT06011135` - Exploring Worry in CFS/ME

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.